- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03585673
Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma (DOSE)
A Phase II Trial of Docetaxel-polymeric Micelles(PM) Plus Oxaliplatin as a First-line Chemotherapy in Patients With Esophageal Squamous Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Few results directly study the combination of docetaxel and oxaliplatin in the squamous cell cancer of the esophagus, but some studies have shown that it is safe to In the phase II study for the patients with gastroesophageal junction adenocarcinoma, a prior study reported the efficacy and safety of the combination therapy of docetaxel 80mg/m2 and oxaliplatin 100mg/m2 every 3 weeks schedule. Entire response rate was 34% and median survival duration was 11.6 months. Over grades 3 anemia and neutropenia were found in 17%, respectively, and non-hematological toxicities were mostly mild to moderate. In this study, a five-day preventive granulocyte colony-stimulating factor (G-CSF) was used to reduce hematology toxicity.
Meanwhile, there was the phase I/II studies of added capecitabine to docetaxel and oxaliplatin with divided schedule d1 and d8 every 3weeks for reducing toxicities. The subjects who participated in this study had at least one previous history of chemotherapy, but overall response rates were 43% and median values for the entire duration of survival were 9.8months. However, the side effects were significant, with 30 % of patients seeing diarrhea of Grade 3 or higher and 17 % seeing infection of Grade 3 or higher (SAE) reported at 37 %.
Looking at the reasons and background for this, the effects of docetaxel on esophageal squamous cell cancer patients are already known, and weekly divided administration has also demonstrated a reasonable level of effectiveness and safety. In studies conducted on gastric and esophageal adenocarcinoma, the combination of docetaxel and oxaliplatin also showed reasonable levels of effects and side effects.
In this study, The investigators wanted to look at the effects and safety of first line docetaxel-PM and oxaliplatin weekly administration chemotherapy for the participants with inoperable or metastatic esophageal squamous cell carcinoma.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sung Yong Oh, MD
- Phone Number: +82512402808
- Email: drosy@dau.ac.kr
Study Locations
-
-
-
Busan, Korea, Republic of, 49201
- Recruiting
- Dong-A University Hospital
-
Contact:
- Sung Yong Oh, MD
- Phone Number: +82512402808
- Email: drosy@dau.ac.kr
-
Contact:
- EunKyung Lee, RN
- Phone Number: +82512405044
- Email: dongahicrc12@naver.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A patient whose squamous cell cancer of the esophagus or esophago-gastric junction has been confirmed by biopsy or cytology.
- A patient who is not subject to local treatment such as surgical excision or concurrent definitive chemoradiotherapy.
- Metastatic or relapsed esophageal cancer patients who planned first line palliative treatment.
- Patients' age over 18
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0-2
- Patient has measurable lesions with RECIST v1.1
Patients with appropriate organ functions, such as the following, within seven days prior to the start of a clinical trial
- Proper bone marrow function (ANC ≥ 1500/uL, Platelets ≥ 100,000/uL and Hb 8/microliter(uL))
- Proper kidney function (serum creatinine ≤ 1.5 mg/L, 24-hour urine test or creatinine clearance ≥ 60 ml/min based on Cockcroft-Gault formula)
- Appropriate liver function (bilirubin ≤ 1.5 mg/dL, transaminases aspartate transaminase (AST or SGOT) and alanine transaminase (AST or SGOT) ≤ 2.5 times normal upper limit)
- Patients with at least three months of an expected life.
- Signing written consent from patients or their legal guardians and understanding the right to withdraw consent at any time without disadvantage.
Exclusion Criteria:
In the case that the following treatment has been received in the past for the local stage treatment more than 6 months from the end of the treatment, enrolment is allowed.
- Neoadjuvant chemotherapy
- Concurrent or sequential chemoradiotherapy
- Adjuvant chemotherapy
- Adjuvant concurrent or sequential chemoradiotherapy
- Definitive concurrent or sequential chemoradiotherapy
- Patients with a history of administration of docetaxel, paclitaxel, or oxaliplatin at any time in the past.
- Patients who have been treated for other active cancers other than esophageal cancer less than five years (but cured kin basal cell cancer or cured cervical carcinoma in situ are excluded).
- The clinically confirmed esophagus obstruction, gastrointestinal bleeding, or perforation (except if the symptoms are sufficiently controlled through proper procedures such as stents).
- Patients with significant, uncontrolled cardiovascular disease, infection, or infectious fever.
- Patients with uncontrolled brain metastasis.
- In the case of major surgery within the first two weeks of clinical trial treatment, the patient must recover sufficiently from the effects of this surgery.
- Patients with pregnancy, breast feeding, or future plans.
- Because of uncontrolled diabetes or diabetic neuropathy, patients who have any subjective symptoms regardless of their degree
- Patients who have taken antihistamine or steroid within four weeks of clinical trial treatment
- In combination with the state of Docetaxel-PM, patients who are not permitted to take combined medication (patients with severe renal dysfunction, para-platin, platinum compound, patients who have hypersensitivity to mannitol, etc.)
- Patients with hypersensitivity history of Polysorbate 80
- A patient who has hypersensitivity history to Docetaxel-PM or oxaliplatin or any drug containing platinum.
- Patients with peripheral sensory neuropathy with functional impairment (may aggravate peripheral neuropathy) prior to clinical trial
Other cases
- Have experienced an infection or other serious medical problems that could cause damage to a patient's functions, making it difficult for the patient to receive treatment in a research plan.
- Mental, neurological, or dementia that can prevent a person from understanding and submitting a written statement and consent form
- Patients who are certain to be out of the clinical trial or who cannot be monitored regularly for the following reasons: For example, psychological, social, family or geographical reasons, or conditions that make it difficult to observe or comply with appropriate clinical trial plans.
- Uncontrolled hepatitis and chronic liver disease
- Other patients who are judged unfit for clinical trials by their physicians and researchers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Docetaxel-PM+Oxaliplatin
|
Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
Other Names:
Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: up to 6 months
|
complete response + partial response by RECIST
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: up to 12 months
|
progression or death
|
up to 12 months
|
Overall survival
Time Frame: up to 12 months
|
death event
|
up to 12 months
|
Adverse event
Time Frame: up tp 12 months
|
Hypersensitivity or any side effects by NCI-Common Terminology Criteria for Adverse Events (CTCAE) v4.03
|
up tp 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Docetaxel
- Oxaliplatin
Other Study ID Numbers
- DAUHIRB-18-041
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Cedars-Sinai Medical CenterRecruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Oslo University HospitalVestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaboratorsRecruitingCancer MetastaticNorway
Clinical Trials on Docetaxel-PM
-
Samyang Biopharmaceuticals CorporationUnknownHead and Neck Squamous Cell CarcinomaKorea, Republic of
-
Columbia UniversityDrexel University; Africa Mental Health Research and Training FoundationNot yet recruitingPsychological Distress | Violence, Domestic
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingStudy of Purinostat Mesylate for Injection in the Treatment of Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B Cell Lymphoma,DLBCLChina
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingHealthy | Overweight and ObesityUnited States
-
University Hospital Inselspital, BerneImaCor, Inc.Completed
-
Anhui Medical UniversityRecruitingTreatment Resistant Depression | Problem Management Plus | Event-Related PotentialsChina
-
Yale UniversityNational Institute on Drug Abuse (NIDA); US Department of Veterans Affairs; National...Completed
-
International Islamic University, IslamabadAid To Leprosy Patients (ALP), Rawalpindi-PakistanCompletedPsychological Distress | Physical Condition, Minor Psychological ComponentPakistan
-
Yale UniversityNational Institute on Drug Abuse (NIDA); US Department of Veterans Affairs; National...Active, not recruiting
-
Rigshospitalet, DenmarkRegion Capital Denmark; Region ZealandRecruitingIschemic Heart DiseaseDenmark